
Reading a Changed Eye Examination and Impact on Therapy
Experts explain how myeloma regimens manage eye toxicity with baseline exams, dose holds, reductions, and longer belantamab dosing intervals to improve safety.
The faculty discuss a patient who feels well but whose eye examination has changed. One panelist explains that every patient needs a baseline eye evaluationfor visual acuity and corneal abnormalities, that simple punctate lesions are not absolute contraindications, and that steroid-related cataracts are better addressed before dosing so they do not confound visual acuity. Changes are typically seen after the second dose. For an asymptomatic grade 2 corneal abnormality, the dose is held,the eye is reassessed before the next scheduled dose, and dosing resumes once findings are back to baseline or grade 1, with a dose level reduction. The second panelist describes how the eye examination and the patient’s comfortimpact the interval.

